StreetInsider.com News Articles

Mizuho prefers this stock among ad names and mega caps

Fri, 24 Jul 2026 06:00:00 -0400

Mizuho Securities named its top pick among online advertising and mega-cap technology stocks heading into second-quarter earnings, citing upside potential to both top- and bottom-line estimates and room for the stock's valuation multiple to expand.

The brokerage placed Meta Platforms (NASDAQ: META) at the top of its pecking order for the sector, reiterating an Outperform rating and the $835 price target.

Analysts led by Lloyd Walmsley said they expect a solid print from Meta, with "muted near-term expectations for ad revenue deceleration," and argued the company should be able to meet or beat consensus advertising revenue estimates given the sustainability of

Mizuho prefers this stock among ad names and mega caps

Fri, 24 Jul 2026 06:00:00 -0400

The brokerage placed Meta Platforms (NASDAQ: META) at the top of its pecking order for the sector, reiterating an Outperform rating and the $835 price target.

Mizuho prefers this stock among ad names and mega caps

Fri, 24 Jul 2026 06:00:00 -0400

The brokerage placed Meta Platforms (NASDAQ: META) at the top of its pecking order for the sector, reiterating an Outperform rating and the $835 price target.

Mizuho prefers this stock among ad names and mega caps

Fri, 24 Jul 2026 06:00:00 -0400

The brokerage placed Meta Platforms (NASDAQ: META) at the top of its pecking order for the sector, reiterating an Outperform rating and the $835 price target.

Mizuho prefers this stock among ad names and mega caps

Fri, 24 Jul 2026 06:00:00 -0400

The brokerage placed Meta Platforms (NASDAQ: META) at the top of its pecking order for the sector, reiterating an Outperform rating and the $835 price target.

Mizuho prefers this stock among ad names and mega caps

Fri, 24 Jul 2026 06:00:00 -0400

The brokerage placed Meta Platforms (NASDAQ: META) at the top of its pecking order for the sector, reiterating an Outperform rating and the $835 price target.

Mizuho prefers this stock among ad names and mega caps

Fri, 24 Jul 2026 06:00:00 -0400

The brokerage placed Meta Platforms (NASDAQ: META) at the top of its pecking order for the sector, reiterating an Outperform rating and the $835 price target.

Mizuho prefers this stock among ad names and mega caps

Fri, 24 Jul 2026 06:00:00 -0400

The brokerage placed Meta Platforms (NASDAQ: META) at the top of its pecking order for the sector, reiterating an Outperform rating and the $835 price target.

Mizuho prefers this stock among ad names and mega caps

Fri, 24 Jul 2026 06:00:00 -0400

The brokerage placed Meta Platforms (NASDAQ: META) at the top of its pecking order for the sector, reiterating an Outperform rating and the $835 price target.

Mizuho prefers this stock among ad names and mega caps

Fri, 24 Jul 2026 06:00:00 -0400

The brokerage placed Meta Platforms (NASDAQ: META) at the top of its pecking order for the sector, reiterating an Outperform rating and the $835 price target.

Mizuho prefers this stock among ad names and mega caps

Fri, 24 Jul 2026 06:00:00 -0400

The brokerage placed Meta Platforms (NASDAQ: META) at the top of its pecking order for the sector, reiterating an Outperform rating and the $835 price target.

Mizuho prefers this stock among ad names and mega caps

Fri, 24 Jul 2026 06:00:00 -0400

The brokerage placed Meta Platforms (NASDAQ: META) at the top of its pecking order for the sector, reiterating an Outperform rating and the $835 price target.

e.l.f. Beauty Announces Earnings Release Date for First Quarter Fiscal 2027 Results

Wed, 22 Jul 2026 16:30:00 -0400

OAKLAND, Calif.--(BUSINESS WIRE)-- e.l.f. Beauty (NYSE: ELF) today announced that it will hold a webcast to discuss its first quarter Fiscal 2027 results on Wednesday, August 5, 2026 at 4:30 p.m. Eastern Time. A press release detailing the Company’s results will be issued prior to the webcast, which will be hosted by Tarang Amin, Chairman and Chief Executive Officer, and Mandy Fields, Senior Vice President and Chief Financial Officer.

The webcast will be broadcasted live at https://investor.elfbeauty.com/stock-and-financial/events-and-presentations. For those unable to listen to the live broadcast, an archived version will be available at the

e.l.f. Beauty Announces Earnings Release Date for First Quarter Fiscal 2027 Results

Wed, 22 Jul 2026 16:30:00 -0400

e.l.f. Beauty Announces Earnings Release Date for First Quarter Fiscal 2027 Results

Wed, 22 Jul 2026 16:30:00 -0400

e.l.f. Beauty Announces Earnings Release Date for First Quarter Fiscal 2027 Results

Wed, 22 Jul 2026 16:30:00 -0400

e.l.f. Beauty Announces Earnings Release Date for First Quarter Fiscal 2027 Results

Wed, 22 Jul 2026 16:30:00 -0400

e.l.f. Beauty Announces Earnings Release Date for First Quarter Fiscal 2027 Results

Wed, 22 Jul 2026 16:30:00 -0400

Actinium reports ATNM-400 cancer therapy data at AACR meeting

Wed, 22 Apr 2026 07:01:58 -0400

Actinium Pharmaceuticals Inc. (NYSE American: ATNM) presented preclinical data for its ATNM-400 targeted radiotherapy at the American Association for Cancer Research Annual Meeting in San Diego. The experimental treatment showed activity across prostate, lung, and breast cancer models in laboratory studies.

ATNM-400 uses the Actinium-225 radioisotope and targets a membrane antigen that the company states is overexpressed in treatment-resistant solid tumors. In prostate cancer models, the therapy demonstrated efficacy in both high and low PSMA-expressing cancers, as well as PSMA-negative models.

The treatment showed greater tumor growth inhibition than osimertinib plus chemotherapy in EGFR-mutant non-small cell lung cancer models. The company also

Actinium reports ATNM-400 cancer therapy data at AACR meeting

Wed, 22 Apr 2026 07:01:58 -0400

The treatment showed greater tumor growth inhibition than osimertinib plus chemotherapy in EGFR-mutant non-small cell lung cancer models. The company also

Actinium reports ATNM-400 cancer therapy data at AACR meeting

Wed, 22 Apr 2026 07:01:58 -0400

The treatment showed greater tumor growth inhibition than osimertinib plus chemotherapy in EGFR-mutant non-small cell lung cancer models. The company also

Actinium reports ATNM-400 cancer therapy data at AACR meeting

Wed, 22 Apr 2026 07:01:58 -0400

The treatment showed greater tumor growth inhibition than osimertinib plus chemotherapy in EGFR-mutant non-small cell lung cancer models. The company also

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer

Wed, 22 Apr 2026 07:00:00 -0400

ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential
In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings
In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings
In breast cancer, new head-to-head data shows

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer

Wed, 22 Apr 2026 07:00:00 -0400

ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential
In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings
In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings
In breast cancer, new head-to-head data shows

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer

Wed, 22 Apr 2026 07:00:00 -0400

ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential
In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings
In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings
In breast cancer, new head-to-head data shows